Recombinant DLL4 (Demcizumab Biosimilar) anticorps
Aperçu rapide pour Recombinant DLL4 (Demcizumab Biosimilar) anticorps (ABIN7675738)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-DLL4 Reference Antibody (demcizumab)
-
Séquence
- QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHWVKQA PGQGLEWIGY ISSYNGATNY NQKFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARDY DYDVGMDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPG,DIVMTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPKL LIYAASNQGS GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEVPW TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
-
Attributs du produit
- Anti-DLL4 Reference Antibody (demcizumab) is expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG2SA
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: DLL4 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- DLL4 (Demcizumab Biosimilar)
-
Classe de substances
- Biosimilar
-
Poids moléculaire
- 145.5 kDa
-
UniProt
- Q9NR61
Antigène
-